Kundaktepe Berrin Papila, Sozer Volkan, Papila Cigdem, Durmus Sinem, Kocael Pinar Cigdem, Simsek Gonul, Gelisgen Remise, Zengin Kagan, Ulualp Kenan, Uzun Hafize
Department of General Surgery, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Department of Biochemistry, Yildiz Technical University, Istanbul, Turkey.
Cancer Manag Res. 2020 Feb 7;12:871-879. doi: 10.2147/CMAR.S227628. eCollection 2020.
Screening approaches using microRNAs (miRNAs) have been gaining increased attention owing to their potential applications in the diagnosis, prognosis, and monitoring of cancer, because aberrant miRNA expression plays a role in the development and advancement of malignancies. The objectives of this study were to characterize mir21, miR31, mir143, mir145, and control RNU43, which are differentially expressed in peripheral blood mononuclear cells (PBMCs) of breast and colorectal cancer patients, compared to that in controls and to establish whether this is specific to breast and colon cancer for use as tumor markers.
Thirty newly diagnosed patients with breast cancer and 30 patients with colorectal cancer were enrolled together with 30 healthy controls. PBMCs were isolated from venous blood samples of individuals. Next, miRNA expression analysis was performed by a two-step method of reverse transcription and qPCR.
The expression levels of miR-143 and miR-31 were significantly decreased, whereas the expression levels of miR-145 and miR-21 were significantly increased in breast cancer patients compared to those in healthy subjects. Moreover, the expression levels of miR-143, miR-145, and miR-21 were significantly increased and, in contrast, the changes in the expression levels of miR-31 were not statistically significant in colon cancer compared to those in healthy subjects. miR-21 exhibited the highest increase in both breast and colon cancers. There was a weak positive correlation between miR-145 and CA-15.3 in patients with breast cancer (r = 0.451; p = 0.012). miR-143 was positively correlated with the TNM stage in colon cancer patients (r = 0.568; p = 0.001).
A biomarker panel composed of miR-21, miR-31, miR-143, and miR-145 in PBMC may provide a new diagnostic approach for the early detection of breast and colon cancer. As miR-21 expression was found to be the highest among all the miRNAs evaluated, it may represent a new tumor biomarker and a candidate therapeutic drug or gene target in colon and breast cancer.
由于微小RNA（miRNA）在癌症诊断、预后和监测中的潜在应用，利用miRNA的筛查方法越来越受到关注，因为异常的miRNA表达在恶性肿瘤的发生和发展中起作用。本研究的目的是对mir21、miR31、mir143、mir145以及对照RNU43进行特征分析，这些在乳腺癌和结直肠癌患者外周血单个核细胞（PBMC）中的表达与对照组存在差异，并确定这是否对乳腺癌和结肠癌具有特异性，以用作肿瘤标志物。
纳入30例新诊断的乳腺癌患者、30例结直肠癌患者以及30例健康对照。从个体的静脉血样本中分离PBMC。接下来，通过逆转录和qPCR两步法进行miRNA表达分析。
与健康受试者相比，乳腺癌患者中miR - 143和miR - 31的表达水平显著降低，而miR - 145和miR - 21的表达水平显著升高。此外，与健康受试者相比，结直肠癌患者中miR - 143、miR - 145和miR - 21的表达水平显著升高，相反，miR - 31表达水平的变化无统计学意义。miR - 21在乳腺癌和结直肠癌中均表现出最高的升高。乳腺癌患者中miR - 145与CA - 15.3之间存在弱正相关（r = 0.451；p = 0.012）。结直肠癌患者中miR - 143与TNM分期呈正相关（r = 0.568；p = 0.001）。
由PBMC中的miR - 21、miR - 31、miR - 143和miR - 145组成的生物标志物组可能为乳腺癌和结直肠癌的早期检测提供一种新的诊断方法。由于发现miR - 21在所有评估的miRNA中表达最高，它可能代表一种新的肿瘤标志物以及结直肠癌和乳腺癌的候选治疗药物或基因靶点。
